🔴 Context Therapeutics is trading 10% down with no clear company-specific catalyst identified

Context Therapeutics is trading down 10.16% at $0.27 on October 13, 2026, with no clear company-specific catalyst identified.

• The latest company announcement located was the September 9 update that the first patient had been dosed in the CT-202 Phase 1 trial.
• Biotech-sector weakness may be contributing: XBI was down 2.01% during the session, without a clear sector-wide catalyst. This backdrop does not establish the cause of the larger individual-stock move.